Patent directory · USPTO A61K / A61P
Patents matching “Agios Pharmaceuticals, Inc.”
93 pharma patents match "Agios Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.
Quick answer
This filtered view shows 93 pharmaceutical patents matching "Agios Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.
Patent results
-
US 10730854
Therapeutically active compounds and their methods of use
granted -
US 10717764
Therapeutically active compounds and their methods of use
granted -
US 10711314
Methods for diagnosing IDH-mutant cell proliferation disorders
granted -
US 10695352
Combination therapy for treating malignancies
granted -
US 10689375
Compounds and their methods of use
granted -
US 10689414
Therapeutically active compounds and their methods of use
granted -
US 10653710
Combination therapy for treating malignancies
granted -
US 10640534
Therapeutically active compositions and their methods of use
granted -
US 10632114
Pyruvate kinase activators for use in therapy
granted -
US 10610125
Methods and compositions for cell-proliferation-related disorders
granted -
US 10449184
Pharmaceutical compositions of therapeutically active compounds
granted -
US 10434105
Therapeutically active compounds and their methods of use
granted -
US 10414740
Glutaminase inhibitors and method of use
granted -
US 10376510
2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer
granted -
US 10329298
Inhibitors of cellular metabolic processes
granted -
US 10294215
Therapeutically active compounds and their methods of use
granted -
US 10202339
Therapeutic compounds and compositions
granted -
US 10201543
Therapeutically active compounds and their methods of use
granted -
US 10188656
Methods of treatment of malignancies
granted -
US 10172864
Therapeutically active compounds and their methods of use
granted -
US 10137130
Methods of treatment of malignancies
granted -
US 10111878
N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer
granted -
US 10105369
Therapeutically active compounds and their methods of use
granted -
US 10101331
Methods of evaluating patients using E-cadherin or vimentin
granted